NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
LAVA Therapeutics Announces Pricing of Initial Public Offering<
25 Mar 2021

LAVA Therapeutics Announces Pricing of Initial Public Offering

Gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by LAVA, are expected to be $100.5 million.
Aura Biosciences Announces Oversubscribed $80 Million Financing<
22 Mar 2021

Aura Biosciences Announces Oversubscribed $80 Million Financing

Ysios Capital joins Aura Biosciences 80MUSD financing
AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial<
10 Mar 2021

AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial

Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication
ONA Therapeutics appoints Mark Throsby to its Board of Directors<
05 Mar 2021

ONA Therapeutics appoints Mark Throsby to its Board of Directors

Dr. Mark Throsby is a biopharmaceutical executive with extensive research experience and a track record of innovation and execution.
New Data Supports High Reperfusion Rate for Anaconda Biomed’s Mechanical Thrombectomy System<
17 Feb 2021

New Data Supports High Reperfusion Rate for Anaconda Biomed’s Mechanical Thrombectomy System

In Vitro Study, Showing Suction Force Correlates with Reperfusion in Hard Clots, Published in Journal of NeuroInterventional Surgery
MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman<
10 Feb 2021

MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman

Financing to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation.
10 Feb 2021

Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease

Sanifit today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead compound SNF472 for the treatment of peripheral arterial disease (PAD) in patients with end-stage kidney disease (ESKD).
09 Feb 2021

CorWave Joins the French Tech 120 Index, a Community That Brings Together the Top French Tech Scale-up Companies

The company develops breakthrough cardiac pumps with the aim of improving the lives of advanced heart failure patients
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board<
29 Jan 2021

Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board.
27 Jan 2021

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.